GGrantIndex
← Leaderboards

Thomas Shea

University Of North Carolina Chapel Hill

Google Scholar ↗PubMed ↗ORCID ↗
$5,623,497
Attributed
$5,623,497
Total exposure
5
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $323.4K · FY2005–13
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13

Funding mix

By agency

NIH$5,623,497 · 5

By mechanism

M01$3,119,910 · 2
U10$1,795,973 · 1
P30$707,614 · 2

Top collaborators

No co-investigators on record.

Most similar at University Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyCombination ChemotherapyBreast NeoplasmsLymphomaClinical TrialsLeadershipProtocols DocumentationLeukemiaColony Stimulating FactorClinical Trial Phase IMalignant NeoplasmsPharmacokineticsHematopoietic Stem CellsFemaleNonhodgkin'S LymphomaDrug Screening /EvaluationAge DifferenceHematopoietic Growth FactorCd34 MoleculeEtoposideOral Administration

Grant awards (34)

Cancer and Leukemia Group B$144,968
U10 · FY2013 · CA · contact PI
Cancer and Leukemia Group B$134,116
U10 · FY2012 · CA · contact PI
Cancer and Leukemia Group B$119,336
U10 · FY2011 · CA · contact PI
Cancer and Leukemia Group B$164,588
U10 · FY2010 · CA · contact PI
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$182,948
P30 · FY2009 · CA · contact PI
Cancer and Leukemia Group B$140,454
U10 · FY2009 · CA · contact PI
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$183,756
P30 · FY2008 · CA · contact PI
Cancer and Leukemia Group B$120,049
U10 · FY2008 · CA · contact PI
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$175,688
P30 · FY2007 · CA · contact PI
Cancer and Leukemia Group B$118,078
U10 · FY2007 · CA · contact PI
Cancer and Leukemia Group B$129,758
U10 · FY2006 · CA · contact PI
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$83,683
P30 · FY2006 · CA · contact PI
Cancer and Leukemia Group B$127,842
U10 · FY2005 · CA
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$81,539
P30 · FY2005 · CA
Cancer and Leukemia Group B$117,282
U10 · FY2004 · CA
Cancer and Leukemia Group B$105,577
U10 · FY2003 · CA
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS$190,747
M01 · FY2002 · RR
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER$190,747
M01 · FY2002 · RR
CANCER AND LEUKEMIA GROUP B$132,005
U10 · FY2002 · CA
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER$294,555
M01 · FY2001 · RR
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS$294,555
M01 · FY2001 · RR
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS$190,747
M01 · FY2001 · RR
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER$190,747
M01 · FY2001 · RR
CANCER AND LEUKEMIA GROUP B$126,887
U10 · FY2001 · CA
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS$294,555
M01 · FY2000 · RR
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER$294,555
M01 · FY2000 · RR
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER$294,555
M01 · FY2000 · RR
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS$294,555
M01 · FY2000 · RR
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS$294,555
M01 · FY2000 · RR
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER$294,555
M01 · FY2000 · RR
CANCER AND LEUKEMIA GROUP B$115,033
U10 · FY2000 · CA
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS$241
M01 · FY2000 · RR
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER$241
M01 · FY2000 · RR
CORE--CLINICAL PROTOCOL$0
P30 · FY2000 · CA